ASAnurag Saraf

Anurag Saraf

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anurag Saraf has a total of 107 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Data from ctDNA Dynamics and Recurrence Patterns after Organ-Sparing Trimodality Therapy for Bladder Cancer

    by Ilana B. Epstein, Adetolani Odogiyon, Stephanie Berg, Yukako Otani, Charlene Mantia, Isabella R. Pompa, Matthew Mossanen, Joshua Wan, Anurag Saraf, Mark Preston, et al.

    Purpose:Trimodality therapy (TMT) is a bladder-sparing treatment approach for patients with muscle-invasive bladder cancer (MIBC). Although plasma circulating tumor DNA (ctDNA) is correlated with treatment response and outcomes following cystectomy for MIBC, the association of plasma ctDNA with clinical outcomes in patients treated with TMT is poorly characterized.Experimental Design:Patients with MIBC who received TMT at Dana-Farber/Brigham and Women’s Cancer Center or Massachusetts General Hospital were consented to a research protocol and underwent ctDNA evaluation at baseline and at regular intervals following TMT using the commercially available Signatera assay. All patients also underwent routine post-TMT surveillance including cross-sectional imaging and cystoscopic evaluation. The association between ctDNA status and clinical disease status was assessed.Results:Eighty-four patients had at least one ctDNA result. Fifty-nine patients had a ctDNA test performed prior to chemoradiotherapy (CRT), and 19 (32%) had detectable ctDNA. Forty-six patients had paired pre- and post-CRT ctDNA results available: nearly all (29/31, 94%) patients with undetectable ctDNA prior to CRT also had undetectable ctDNA at the first post-CRT assessment, whereas 11 of 15 (73%) patients with detectable ctDNA prior to CRT converted to undetectable ctDNA following CRT. Sixteen (19%) patients developed metastatic disease, and detectable ctDNA following CRT was strongly correlated with metastatic recurrence (P < 0.0001). Conversely, no patients with an isolated muscle-invasive (n = 5) or non–muscle invasive (n = 7) bladder recurrence had a post-TMT test demonstrating detectable ctDNA prior to recurrence.Conclusions:ctDNA detectability is strongly correlated with metastatic but not local disease recurrence in patients with MIBC following TMT.

  • Open Access

    Supplementary Data 1 from ctDNA Dynamics and Recurrence Patterns after Organ-Sparing Trimodality Therapy for Bladder Cancer

    by Ilana B. Epstein, Adetolani Odogiyon, Stephanie Berg, Yukako Otani, Charlene Mantia, Isabella R. Pompa, Matthew Mossanen, Joshua Wan, Anurag Saraf, Mark Preston, et al.

  • Top Cited Papers
    Open Access

    ctDNA Dynamics and Recurrence Patterns after Organ-Sparing Trimodality Therapy for Bladder Cancer

    by Ilana B. Epstein, Adetolani Odogiyon, Stephanie Berg, Yukako Otani, Charlene Mantia, Isabella R. Pompa, Matthew Mossanen, Joshua Wan, Anurag Saraf, Mark Preston, et al.

    Purpose: Trimodality therapy (TMT) is a bladder-sparing treatment approach for patients with muscle-invasive bladder cancer (MIBC). Although plasma circulating tumor DNA (ctDNA) is correlated with treatment response and outcomes following cystectomy for MIBC, the association of plasma ctDNA with clinical outcomes in patients treated with TMT is poorly characterized. Experimental Design: Patients with MIBC who received TMT at Dana-Farber/Brigham and Women’s Cancer Center or Massachusetts General Hospital were consented to a research protocol and underwent ctDNA evaluation at baseline and at regular intervals following TMT using the commercially available Signatera assay. All patients also underwent routine post-TMT surveillance including cross-sectional imaging and cystoscopic evaluation. The association between ctDNA status and clinical disease status was assessed. Results: Eighty-four patients had at least one ctDNA result. Fifty-nine patients had a ctDNA test performed prior to chemoradiotherapy (CRT), and 19 (32%) had detectable ctDNA. Forty-six patients had paired pre- and post-CRT ctDNA results available: nearly all (29/31, 94%) patients with undetectable ctDNA prior to CRT also had undetectable ctDNA at the first post-CRT assessment, whereas 11 of 15 (73%) patients with detectable ctDNA prior to CRT converted to undetectable ctDNA following CRT. Sixteen (19%) patients developed metastatic disease, and detectable ctDNA following CRT was strongly correlated with metastatic recurrence (P < 0.0001). Conversely, no patients with an isolated muscle-invasive (n = 5) or non–muscle invasive (n = 7) bladder recurrence had a post-TMT test demonstrating detectable ctDNA prior to recurrence. Conclusions: ctDNA detectability is strongly correlated with metastatic but not local disease recurrence in patients with MIBC following TMT.


  • Association of Sarcopenia With Toxicity and Survival in Patients With Lung Cancer, a Multi-Institutional Study With External Dataset Validation

    by Anurag Saraf, John He, Kee-Young Shin, Jakob Weiss, Mark M. Awad, Justin Gainor, Benjamin H. Kann, David C. Christiani, Hugo J.W.L. Aerts, Raymond H. Mak


  • Open Access

    Optimizing Care Across the Continuum for Older Adults with Lung Cancer: A Review

    by Leah Thompson, Caterina Florissi, Jaewon Yoon, Anupama Singh, Anurag Saraf

    Older adults with lung cancer experience inferior clinical outcomes compared to their younger counterparts. This review provides the scaffolding to address these disparities by delineating (1) the distinct and varied care needs of older adults with lung malignancies, (2) evidence-based measures for identifying subgroups within this population meriting tailored approaches to care, (3) age-specific considerations for the selection of cancer-directed therapy, and (4) opportunities for future work to enhance clinical outcomes and care delivery.


  • Association of Sarcopenia With Toxicity-Related Discontinuation of Adjuvant Endocrine Therapy in Women With Early-Stage Hormone Receptor–Positive Breast Cancer

    by Anurag Saraf, Ismail Tahir, Bonnie Hu, Anna-Sophia W. Dietrich, P. Erik Tonnesen, Gregory C. Sharp, Gayle Tillman, Eric J. Roeland, Ryan D. Nipp, Amy Comander, et al.


  • Open Access

    Future of Radiation Oncology Education: Transforming Scholarly Teaching Into Medical Education Scholarship

    by Anurag Saraf, Graham Boyd, Alexandra De Leo, Phylicia D. Gawu, Chelsea C. Pinnix, Steve Braunstein, Rachel Jimenez, Idalid Franco, Lisa Singer

    Crossref makes research objects easy to find, cite, link, assess, and reuse. We’re a not-for-profit membership organization that exists to make scholarly communications better.

  • Long-term outcomes and late toxicity of adult medulloblastoma treated with combined modality therapy: A contemporary single-institution experience

    by Anurag Saraf, Torunn I Yock, Andrzej Niemierko, Kevin S Oh, William T Curry, William E Butler, Deborah A Forst, Isabel Arrillaga-Romany, David H Ebb, Nancy J Tarbell, et al.

    Background: Medulloblastoma (MB) is a rare central nervous system malignancy of adults, with limited contemporary studies to define treatment guidelines and expected late toxicity. Methods: A single-center, retrospective study was conducted of patients age ≥18 years from 1997–2019 with MB and who were treated with postoperative radiotherapy. Late toxicity was defined as a minimum of 18 months from diagnosis. Overall survival (OS) and progression-free survival (PFS) were characterized using Kaplan-Meier and Cox regression analyses. Results: Fifty-nine patients met criteria, with median age of 25 years (range 18–62 y) and median follow-up of 6.5 years (range 0.7–23.1 y). At diagnosis, 68% were standard-risk, 88% Chang M0, and 22% with anaplastic histology. Gross total resection was achieved in 75%; median craniospinal irradiation dose was 30.6 Gy (relative biological effectiveness [RBE]), median total dose was 54.0 Gy (RBE), 80% received proton radiotherapy; 81% received chemotherapy. 5 year PFS and OS were 86.5% and 95.8%, respectively; 10 year PFS and OS were 83.9% and 90.7%, respectively. Anaplastic histology was associated with worse PFS (P = .04). Among eight recurrences, 25% presented after 5 years. Most common grade ≥2 late toxicities were anxiety/depressive symptoms (30%), motor dysfunction (25%), and ototoxicity (22%). Higher posterior fossa radiation dose was associated with increased risk of late toxicity, including worse cognitive dysfunction (P = .05). Conclusions: Adults with MB have favorable survival outcomes, but late failures and toxicity are not uncommon. Better understanding of prognostic factors, possibly from molecular subtyping, may help to define more personalized treatments for patients with high risk of recurrence and long-term treatment sequelae.


  • Fractionated Proton Radiation Therapy and Hearing Preservation for Vestibular Schwannoma: Preliminary Analysis of a Prospective Phase 2 Clinical Trial

    by Anurag Saraf, Luke R. G. Pike, Kevin H. Franck, Nora K. Horick, Beow Y. Yeap, Barbara C. Fullerton, Irene S. Wang, Mohamed E. Abazeed, Michael J. McKenna, William A. Mehan, et al.

    BACKGROUND: Local management for vestibular schwannoma (VS) is associated with excellent local control with focus on preserving long-term serviceable hearing. Fractionated proton radiation therapy (FPRT) may be associated with greater hearing preservation because of unique dosimetric properties of proton radiotherapy. OBJECTIVE: To investigate hearing preservation rates of FPRT in adults with VS and secondarily assess local control and treatment-related toxicity. METHODS: A prospective, single-arm, phase 2 clinical trial was conducted of patients with VS from 2010 to 2019. All patients had serviceable hearing at baseline and received FPRT to a total dose of 50.4 to 54 Gy relative biological effectiveness (RBE) over 28 to 30 fractions. Serviceable hearing preservation was defined as a Gardner–Robertson score of 1 to 2, measured by a pure tone average (PTA) of ≤50 dB and a word recognition score (WRS) of ≥50%. RESULTS: Twenty patients had a median follow-up of 4.0 years (range 1.0-5.0 years). Local control at 4 years was 100%. Serviceable hearing preservation at 1 year was 53% (95% CI 29%-76%), and primary end point was not yet reached. Median PTA and median WRS both worsened 1 year after FPRT (P < .0001). WRS plateaued after 6 months, whereas PTA continued to worsen up to 1 year after FPRT. Median cochlea D90 was lower in patients with serviceable hearing at 1 year (40.6 Gy [RBE] vs 46.9 Gy [RBE]), trending toward Wilcoxon rank-sum test statistical significance (P = .0863). Treatment was well-tolerated, with one grade 1 cranial nerve V dysfunction and no grade 2+ cranial nerve dysfunction. CONCLUSION: FPRT for VS did not meet the goal of serviceable hearing preservation. Higher cochlea doses trended to worsening hearing preservation, suggesting that dose to cochlea correlates with hearing preservation independent of treatment modality.


  • Open Access

    Healthcare Disparities and Outcomes of Cancer Patients in a Community Setting from a COVID-19 Epicenter

    by Brianna M. Jones, Eric J. Lehrer, Anurag Saraf, Zahra Shafaee, Lucas Resende Salgado, Virginia W. Osborn

    There have been numerous studies demonstrating how cancer patients are at an increased risk of mortality. Within New York City, our community hospital emerged as an epicenter of the first wave of the pandemic in the spring of 2020 and serves a unique population that is predominately uninsured, of a lower income, and racially/ethnically diverse. In this single institution retrospective study, the authors seek to investigate COVID-19 diagnosis, severity and mortality in patients with an active cancer diagnosis. Demographic, clinical characteristics, treatment, SARS-CoV-2 laboratory results, and outcomes were evaluated. In our community hospital during the first wave of the COVID-19 pandemic in the United States, patients with active cancer diagnosis appear to be at increased risk for mortality (30%) and severe events (50%) due to the SARS-CoV-2 infection compared to the general population. A higher proportion of active cancer patients with Medicaid insurance, Hispanic ethnicity, other race, and male sex had complications and death from COVID-19 infection. The pandemic has highlighted the health inequities that exist in vulnerable patient populations and underserved communities such as ours.